Immune-mediated cytopenia following hematopoietic stem cell transplantation (HSCT) has been observed in patients with primary immune deficiency (PID), particularly in those patients receiving umbilical cord blood transplants. [1] [2] [3] [4] [5] The association with other non-malignant disorders, and concomitant risk factors, is not fully understood. 6 We describe a fatal case of immune-mediated hemolytic anemia in a patient with immune deficiency, followed by a single-center analysis of pediatric patients with PID and other non-malignant disorders developing immune cytopenia as a complication of HSCT.
A 9-month-old female presented to our hospital with failure to thrive, diarrhea and history of bacterial urinary tract infection and pneumonia. Her past medical history included an uncomplicated birth at term and no family history of immune deficiency. An immune deficiency work-up was performed and demonstrated hypogammaglobulinemia (IgG 178 mg/dL) and lymphopenia (absolute lymphocyte count o 500 cells/μL). Peripheral blood flow cytometry revealed severe deficiency of T (o 100 cells/mL) and B lymphocytes ( o50 cells/mL) and analysis of both CD4+ and CD8+ T cells demonstrated absence of CD45RA expression. Mitogen testing revealed decreased T-cell proliferation in response to multiple stimulants. Genetic testing was performed, which revealed two heterozygous RAG1 mutations. The first mutation was the previously described R975Q mutation. 7 The second mutation was a novel c.908 arginine to cytidine substitution resulting in a histidine substitution for proline at position 303 (P303H), and this mutation is considered to be a disease-causing alteration. Based on these results and her clinical presentation, she was diagnosed with Omenn syndrome, and was referred for HSCT. Omenn syndrome is a form of severe combined immune deficiency (SCID) where T cells (typically an oligoclonal population) are present, and is often termed 'leaky' SCID. These patients frequently develop T-cell-mediated erythroderma and diarrhea with infections secondary to barrier breakdown. Omenn syndrome is uniformly fatal without HSCT. 8 Donor search was performed with no suitable related or unrelated donor identified, and she subsequently underwent an ABO mismatched, umbilical cord blood transplant (four of six serologic and allele HLA-matched) following reduced intensity preparative regimen using fludarabine and melphalan with alemtuzumab (Campath) serotherapy. 9 GvHD prophylaxis consisted of cyclosporine A and mycophenolate mofetil. Following transplant, the patient developed lower gastrointestinal GvHD (Stage 1, Grade II) and was treated with oral steroids with a complete resolution. Over the first 3 months post HSCT, the patient's hemoglobin was 410 g/dL consistently, with negative Coombs testing, and normal hemolysis labs (normal reticulocyte count, bilirubin and lactate dehydrogenase (LDH)). On approximately day +120 post-HSCT, she developed a progressive and treatment-refractory Coombs-positive hemolytic anemia. She demonstrated multiple warm antibodies, including anti-Duffy A and anti-Fya, coupled with increased LDH (44000 U/L), bilirubin (indirect) and reticulocyte count, decreased haptoglobin and positive urinary hemoglobin. Parvovirus, cytomegalovirus and Epstein-Barr virus serum testing, as well as other viral screening were negative. Prior to and following onset of positive Coombs testing, the patient was receiving monthly IVIG therapy, as per standard protocol for recipients of allogeneic HSCT at this institution. Anti-platelet and anti-neutrophil antibodies were negative prior to and following onset of Coombs-positive anemia.
Over the ensuing months, the patient received high-dose (1 gm/kg) intravenous immune globulin (IVIG), steroids (⩽2 mg/ kg/day), rituximab (four doses), and calcineurin inhibitors (CNI) for treatment of her immune cytopenia. Red blood cell transfusions, using ABO and Rh-matched, 'least incompatible' units, were administered as supportive care. Figure 1a summarizes the patient's hemoglobin and reticulocyte course over this period, and includes the prescribed therapies. Despite extensive treatment, this patient's hemoglobin did not demonstrate significant improvement and Coombs testing remained positive throughout her therapies. Three days following a RBC transfusion, the patient presented to a local emergency room with a hemoglobin of 2 g/dL, and subsequently experienced multi-organ failure and died from complications.
To determine the incidence of post-transplant IC in patients with non-malignant disorders, we performed a retrospective review of pediatric patients undergoing HSCT at our institution for PID and compared them to a cohort of transplanted non-malignant patients without PID, which we refer to as non-malignant other (NMO). We performed analyses on 20 consecutively transplanted patients from the years 2010 to 2016 in both diagnosis categories and evaluated for the presence of clinically significant immune cytopenias, as defined by presence of cytopenia concomitant with positive testing for antibodies (that is, Coombs, anti-neutrophil or anti-platelet antibody), similar to previous studies. 2 Patient characteristics are shown in Table 1 . As shown, compared to NMO patients, PID patients were more likely to be younger (P = 0.003). More PID patients received reduced intensity and/or non-myeloablative preparative regimens (that is, serotherapy alone or no preparative regimen), although this difference was not statistically significant. PID and NMO patients experienced similar incidence and severity of acute and chronic GvHD. Statistical analysis of categorical variables was performed using Fisher's exact test and Student's t-test was utilized to compare means between continuous variables. Following HSCT, six PID patients developed immune cytopenias, defined as clinically relevant cytopenia associated with positive antibody testing (five Coombs, four anti-platelet), similar to criteria described in previous studies. 2 For hemolysis, we also obtained evidence of either reticulocytosis or increased LDH. All patients meeting these criteria required treatment for this complication. Similarly, five NMO patients developed post-transplant immune cytopenia, with two requiring therapy. As seen in Figure 1b , the incidence of IC affecting more than a single hematopoietic cell line was similar in patients with PID (three) and NMO (three). The incidence of severe IC (that is, requiring therapeutic intervention) was higher in patients with PID as compared to those with NMO (Figure 1c ), but this difference was not statistically significant. Interestingly, in all five NMO patients IC arose in the context of chronic GvHD, while only two of six PID patients with immune cytopenia had concomitant cGvHD.
PID patients demonstrated more severe cytopenias (six patients requiring high-dose steroids and rituximab therapy, compared to two patients with NMO), but this was not statistically significant. Patients developing post-transplant IC demonstrated a worse overall survival compared to those patients without IC (Figure 1d ), and this difference was statistically significant (P = 0.01). Mortality resulting directly from IC occurred more frequently in PID patients compared to patients with NMO, but this was not significant.
The reported patient received an ABO major mismatched UCB transplant and later developed severe IC. As shown in Table 1 , PID patients had a similar rate of ABO mismatched transplants compared to NMO patients. In those patients receiving a major ABO mismatched stem cell graft, there was an increased risk of developing IC (P = 0.06), however this was not significant. Previous reports have indicated that ABO major incompatibility between donor and recipient can induce early hemolytic events, as well as delayed red blood cell recovery. 10, 11 Recipients of major ABO mismatched grafts can also develop pure red cell aplasia. Studies on immune-mediated hemolysis and immune cytopenias have not consistently demonstrated an association with donor/ recipient ABO incompatibility. 2, 6, 13 Previous studies have demonstrated that recipients of umbilical cord blood transplants (UCBT) are at increased risk of developing IC, particularly in young recipients. 2, 14 While the patient described above received an UCBT and experienced fatal immune cytopenia; we did not find an increased incidence or severity of IC in patients with non-malignant disorders receiving this graft type. In UCBT recipients, four of ten developed IC while in recipients of unrelated bone marrow or peripheral blood stem cell transplants, seven of thirty developed IC.
Patients receiving unrelated donor grafts have been shown previously to be at increased risk of developing IC. 13 In our patient population, IC occurred in 27% of patients receiving either matched related donor graft (3 of 11 patients) or an unrelated donor graft (8 of 29). The development of chronic GvHD has also been shown to be a risk factor for development of IC. 13, 15 Of those patients diagnosed with chronic GvHD, 33% developed concomitant IC (5 of 15 patients) while 24% of patients experienced IC in the absence of chronic GvHD (6 of 25 patients). While only 33% of PID patients had IC in the presence of chronic GvHD compared to 60% of NMO patients, this difference was not statistically significant (P = 0.5).
Our data suggests severe post-transplant immune cytopenia may occur frequently in pediatric primary immune deficiency patients and indicates the need for close monitoring and aggressive treatment for these patients following HSCT. It is possible that IC in these patients represented another manifestation of GvHD, however, the similar rates of IC in patients with or without GvHD would not support this possibility. We recognize that small patient numbers, as well as the diversity of primary diagnoses, limit our ability to draw conclusions from this study. In addition, the retrospective nature of this study may introduce a selection bias. However, our data demonstrate the impact of IC on patient survival, and indicates that patients with PID may be at increased risk of developing IC, particularly severe disease. Future studies should analyze the incidence of IC and the severity of this disease in pediatric patients undergoing allogeneic HSCT.
